CN110475564A - 用利那洛肽的修饰的或延迟释放制剂治疗肠易激综合征的方法 - Google Patents

用利那洛肽的修饰的或延迟释放制剂治疗肠易激综合征的方法 Download PDF

Info

Publication number
CN110475564A
CN110475564A CN201780087073.0A CN201780087073A CN110475564A CN 110475564 A CN110475564 A CN 110475564A CN 201780087073 A CN201780087073 A CN 201780087073A CN 110475564 A CN110475564 A CN 110475564A
Authority
CN
China
Prior art keywords
linaclotide
pain
baseline
week
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780087073.0A
Other languages
English (en)
Chinese (zh)
Inventor
A.哈沙什
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ironwood Pharmaceuticals Inc
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of CN110475564A publication Critical patent/CN110475564A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780087073.0A 2016-12-21 2017-12-21 用利那洛肽的修饰的或延迟释放制剂治疗肠易激综合征的方法 Pending CN110475564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437566P 2016-12-21 2016-12-21
US62/437566 2016-12-21
PCT/US2017/067814 WO2018119191A1 (en) 2016-12-21 2017-12-21 Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide

Publications (1)

Publication Number Publication Date
CN110475564A true CN110475564A (zh) 2019-11-19

Family

ID=61022424

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087073.0A Pending CN110475564A (zh) 2016-12-21 2017-12-21 用利那洛肽的修饰的或延迟释放制剂治疗肠易激综合征的方法

Country Status (10)

Country Link
EP (1) EP3558337A1 (enExample)
JP (2) JP2020512292A (enExample)
CN (1) CN110475564A (enExample)
AU (1) AU2017379082A1 (enExample)
BR (1) BR112019012689A2 (enExample)
CA (1) CA3048195A1 (enExample)
EA (1) EA201991531A1 (enExample)
MA (1) MA47112A (enExample)
MX (2) MX2019007574A (enExample)
WO (1) WO2018119191A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140528A1 (en) * 2019-06-10 2020-12-17 Wilmin Bartolini Treatment of abdominal pain associated with diarrhea-predominant irritable bowel syndrome
WO2023097309A1 (en) * 2021-11-29 2023-06-01 Ironwood Pharmaceuticals, Inc. Pharmaceutical compositions for the treatment of visceral pain
WO2023196821A2 (en) * 2022-04-04 2023-10-12 Thomas Jefferson University Targeting neuropod cell gucy2c to control visceral pain and appetite

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
US20140005128A1 (en) * 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
CN104053449A (zh) * 2011-08-17 2014-09-17 硬木药品公司 胃肠疾患的治疗
CN105338958A (zh) * 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
US20160310559A1 (en) * 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Delayed Release Compositions of Linaclotide
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2328601B1 (en) 2008-08-15 2020-01-22 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
CA2790213A1 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045239A1 (en) * 2009-08-13 2013-02-21 Ironwood Pharmaceuticals, Inc. Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists
US20140005128A1 (en) * 2010-08-11 2014-01-02 Forest Laboratories Holdings Limited Treatments of gastrointestinal disorders
CN104053449A (zh) * 2011-08-17 2014-09-17 硬木药品公司 胃肠疾患的治疗
CN105338958A (zh) * 2013-01-15 2016-02-17 铁木医药有限公司 胆汁酸螯合剂的胃内滞留缓释口服剂型
US20160310559A1 (en) * 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Delayed Release Compositions of Linaclotide
WO2016197042A1 (en) * 2015-06-05 2016-12-08 Ironwood Pharmaceuticals, Inc. Modified or targeted release formulations of linaclotide

Also Published As

Publication number Publication date
WO2018119191A9 (en) 2018-10-18
MA47112A (fr) 2019-10-30
MX2019007574A (es) 2019-09-04
MX2023008839A (es) 2023-08-14
EP3558337A1 (en) 2019-10-30
JP2022093472A (ja) 2022-06-23
JP2020512292A (ja) 2020-04-23
CA3048195A1 (en) 2018-06-28
EA201991531A1 (ru) 2019-11-29
WO2018119191A1 (en) 2018-06-28
BR112019012689A2 (pt) 2019-11-19
AU2017379082A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
JP7483656B2 (ja) リナクロチドの遅延放出組成物
JP2022093472A (ja) リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
EP3302440B1 (en) Modified or targeted release formulations of linaclotide
US20230346878A1 (en) Treatment of Abdominal Pain Associated with Diarrhea-Predominant Irritable Bowel Syndrome
US20250073301A1 (en) Delayed Release Compositions of Linaclotide
HK40081509A (en) Delayed release compositions of linaclotide
HK40017265A (en) Methods of treating irritable bowel syndrome with modified or delayed release formulations of linaclotide
HK40051190A (en) Delayed release compositions of linaclotide
HK1237651A1 (en) Delayed release compositions of linaclotide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017265

Country of ref document: HK